Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'selective serotonin reuptake inhibitors'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder / Nicole B. GIDAYA in Journal of Autism and Developmental Disorders, 44-10 (October 2014)
[article]
Titre : In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Nicole B. GIDAYA, Auteur ; Brian K. LEE, Auteur ; Igor BURSTYN, Auteur ; Michael YUDELL, Auteur ; Erik L. MORTENSEN, Auteur ; Craig J. NEWSCHAFFER, Auteur Article en page(s) : p.2558-2567 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders Selective serotonin reuptake inhibitors Pregnancy Depression Index. décimale : PER Périodiques Résumé : We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers. En ligne : http://dx.doi.org/10.1007/s10803-014-2128-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=240
in Journal of Autism and Developmental Disorders > 44-10 (October 2014) . - p.2558-2567[article] In Utero Exposure to Selective Serotonin Reuptake Inhibitors and Risk for Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Nicole B. GIDAYA, Auteur ; Brian K. LEE, Auteur ; Igor BURSTYN, Auteur ; Michael YUDELL, Auteur ; Erik L. MORTENSEN, Auteur ; Craig J. NEWSCHAFFER, Auteur . - p.2558-2567.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 44-10 (October 2014) . - p.2558-2567
Mots-clés : Autism spectrum disorders Selective serotonin reuptake inhibitors Pregnancy Depression Index. décimale : PER Périodiques Résumé : We investigated whether there is an association between increased risk for autism spectrum disorders (ASD) and selective serotonin reuptake inhibitors (SSRIs) used during pregnancy. This study used Denmark’s health and population registers to obtain information regarding prescription drugs, ASD diagnosis, and health and socioeconomic status. There were 1.5 % of cases and 0.7 % of controls exposed to SSRIs during the pregnancy period, and higher effect estimates observed with longer use. We found evidence that in utero exposure to SSRIs increases a child’s risk associated with ASD. These results, while adding to the limited knowledge on prenatal pharmacological exposures as potential ASD risk factors, need to be balanced against the benefits of indicated medication use by pregnant mothers. En ligne : http://dx.doi.org/10.1007/s10803-014-2128-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=240 Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy / Rebecca A. HARRINGTON in Autism Research, 6-3 (June 2013)
[article]
Titre : Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy Type de document : Texte imprimé et/ou numérique Auteurs : Rebecca A. HARRINGTON, Auteur ; Li-Ching LEE, Auteur ; Rosa M. CRUM, Auteur ; Andrew W. ZIMMERMAN, Auteur ; Irva HERTZ-PICCIOTTO, Auteur Année de publication : 2013 Article en page(s) : p.149-168 Langues : Anglais (eng) Mots-clés : autism spectrum disorders serotonin selective serotonin reuptake inhibitors pregnancy Index. décimale : PER Périodiques Résumé : Serotonin, a neurotransmitter found throughout the brain and body, has long been of interest in autism. Repeated findings of elevated platelet serotonin levels in approximately one third of children with autism has led some to believe that dysfunctional serotonin signaling may be a causal mechanism for the disorder. Because serotonin is critical to fetal brain development, concerns have arisen regarding prenatal exposure to substances that manipulate serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs). This review examines evidence regarding the serotonin system and autism spectrum disorders (ASD), as well as what the literature has reported thus far on developmental effects of prenatal exposure to SSRIs. Possible mechanisms by which SSRIs could affect the fetus during pregnancy and clinical implications are also discussed. Though the majority of studies conducted in infants and children suggest prenatal exposure to SSRIs does not affect neurodevelopment, interpretation must be tempered given small sample sizes. The only published study that focused on prenatal SSRI exposure and ASD found an increased risk with exposure to SSRIs, especially during the first trimester. Obstacles that will be faced in future research are isolating medication effects from maternal depression and, given the infrequent occurrence of exposure and outcome, obtaining an adequate sample size. Whether serotonin is an etiologic factor in ASD, and what it points to as a marker for subgrouping, remains unclear. Understanding how the development of ASD might be affected by prenatal factors that influence serotonin levels, such as SSRIs, could identify modifiable targets for prevention. En ligne : http://dx.doi.org/10.1002/aur.1288 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202
in Autism Research > 6-3 (June 2013) . - p.149-168[article] Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy [Texte imprimé et/ou numérique] / Rebecca A. HARRINGTON, Auteur ; Li-Ching LEE, Auteur ; Rosa M. CRUM, Auteur ; Andrew W. ZIMMERMAN, Auteur ; Irva HERTZ-PICCIOTTO, Auteur . - 2013 . - p.149-168.
Langues : Anglais (eng)
in Autism Research > 6-3 (June 2013) . - p.149-168
Mots-clés : autism spectrum disorders serotonin selective serotonin reuptake inhibitors pregnancy Index. décimale : PER Périodiques Résumé : Serotonin, a neurotransmitter found throughout the brain and body, has long been of interest in autism. Repeated findings of elevated platelet serotonin levels in approximately one third of children with autism has led some to believe that dysfunctional serotonin signaling may be a causal mechanism for the disorder. Because serotonin is critical to fetal brain development, concerns have arisen regarding prenatal exposure to substances that manipulate serotonin levels, such as selective serotonin reuptake inhibitors (SSRIs). This review examines evidence regarding the serotonin system and autism spectrum disorders (ASD), as well as what the literature has reported thus far on developmental effects of prenatal exposure to SSRIs. Possible mechanisms by which SSRIs could affect the fetus during pregnancy and clinical implications are also discussed. Though the majority of studies conducted in infants and children suggest prenatal exposure to SSRIs does not affect neurodevelopment, interpretation must be tempered given small sample sizes. The only published study that focused on prenatal SSRI exposure and ASD found an increased risk with exposure to SSRIs, especially during the first trimester. Obstacles that will be faced in future research are isolating medication effects from maternal depression and, given the infrequent occurrence of exposure and outcome, obtaining an adequate sample size. Whether serotonin is an etiologic factor in ASD, and what it points to as a marker for subgrouping, remains unclear. Understanding how the development of ASD might be affected by prenatal factors that influence serotonin levels, such as SSRIs, could identify modifiable targets for prevention. En ligne : http://dx.doi.org/10.1002/aur.1288 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=202